Back to Search
Start Over
Decompression Surgery in Elderly Patients with Hemifacial Spasm Refractory to Botulinum Toxin.
- Source :
-
Movement disorders clinical practice [Mov Disord Clin Pract] 2024 Aug; Vol. 11 (8), pp. 966-972. Date of Electronic Publication: 2024 May 23. - Publication Year :
- 2024
-
Abstract
- Background: Botulinum toxin is an effective treatment for hemifacial spasm in elderly patients. However, some patients do not tolerate the side effects and frequency of botulinum toxin treatments.<br />Objectives: The purpose of this study was to evaluate the characteristics and outcomes of a cohort of elderly patients referred by neurologists for surgical decompression of the facial nerve following botulinum toxin treatment.<br />Methods: In a prospective cohort study, logistic regression was used to detect potential predictors of spasm-freedom after surgical decompression of the facial nerve in elderly patients that received ≤8 and >8 botulinum toxin treatments for hemifacial spasm before surgery. Age, sex, side, preoperative symptom duration, and preoperative botulinum toxin treatment were assessed as potential predictors of spasm-freedom at last follow-up.<br />Results: Of 76 elderly patients with hemifacial spasm treated with botulinum toxin and microvascular decompression, with at least 2-years of follow-up (median, 44.5 months), 84.2% were spasm-free at last follow-up. Age (P = 0.38), sex (P = 0.59), side (P = 0.15), preoperative symptom duration (P = 0.7), and number of preoperative botulinum toxin treatments (P = 0.3) were not predictors of long-term spasm-freedom. Permanent ipsilateral hearing loss was the most frequent complication (3.9%).<br />Conclusion: This study provides evidence that elderly patients can undergo botulinum toxin treatment for hemifacial spasm without compromising their likelihood of achieving spasm-freedom with future surgical decompression. Therefore, surgical decompression of the facial nerve is an effective therapy for elderly patients with hemifacial spasm refractory to botulinum toxin.<br /> (© 2024 International Parkinson and Movement Disorder Society.)
- Subjects :
- Humans
Female
Male
Aged
Neuromuscular Agents therapeutic use
Neuromuscular Agents administration & dosage
Aged, 80 and over
Decompression, Surgical methods
Decompression, Surgical adverse effects
Prospective Studies
Treatment Outcome
Botulinum Toxins therapeutic use
Botulinum Toxins administration & dosage
Botulinum Toxins, Type A therapeutic use
Botulinum Toxins, Type A administration & dosage
Facial Nerve surgery
Facial Nerve drug effects
Facial Nerve physiopathology
Cohort Studies
Middle Aged
Hemifacial Spasm surgery
Hemifacial Spasm drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 2330-1619
- Volume :
- 11
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- Movement disorders clinical practice
- Publication Type :
- Academic Journal
- Accession number :
- 38779725
- Full Text :
- https://doi.org/10.1002/mdc3.14064